Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Aim. To study antihypertensive efficacy and safety of valsartan-based therapy (Diovan, Novartis Pharma) as well as patient’s compliance and influence of treatment on several aspects of sexual function.

Material and methods. 114 doctors from 81 medical institutions of Russia participated in this prospective multicenter observation study. 650 hypertensive patients (average age 53,9±0,4 y.o.) were enrolled. The evaluation of therapy efficacy was based on analysis of systolic (SBP) and diastolic (DBP) blood pressure (BP) changes. Safety and compliance of treatment was also analyzed. The evaluation of sexual function was performed with 5 universal questions selected form the International Index of Erectile Function. These questions could be asked in both men and women. The valsartan dose was 80-320 mg OD. A combination of the valsartan with hydrochlorothiazide (12,5-25 mg/d), amlodipine (5-10 mg/d) or any other antihypertensive was allowed.

Results. Significant similar decrease of SBP and DBP was observed in smoking and non-smoking patients (37,5/18,5 and 37,6/15,9 mm Hg respectively, р<0,01 vs baseline). 312 patients (56,9% men, 43,1% women) completed sexual function survey. After 12 weeks of treatment the number of patients without sexual activity and with 1-2 successful sexual attempts in the last 4 weeks significantly decreased from 22 to 16% and from 44 to 30% respectively (р<0,05). Significant increase in the number of patients with 5-6 and 7-10 successful sexual attempts was observed (from 7 to 20% and from 0 to 7% respectively, р<0,05). The treatment resulted in significant increase in the number of patients, who characterized their sexual life satisfaction as “very satisfied” (from 11 to 25%, р<0,01).

Conclusion. During the course of effective antihypertensive treatment there was a significant increase in sexual function and general satisfaction with sexual life in patients with arterial hypertension, which could have favorable long-term consequences in increased compliance to the antihypertensive therapy.

About the Authors

V. I. Podzolkov
Moscow Medical Academy named after I.M.Setchenov
Russian Federation
Bolshaya Pirogovskaya ul. 6, Moscow, 119991

V. A. Bulatov
Novartis Pharma
WSJ-27.4.37, Basel CHBS-4002

A. V. Vigdorchik
Novartis Pharma
Russian Federation
Sadovnicheskaya ul. 82, stroen. 2, Moscow 115035


1. Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105-87.

2. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Кардиоваскулярная терапия и профилактика 2008; 7(6 приложение 2):1-32.

3. Mancia G., Laurent S., Agabiti-Rosei E. et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18(6):308-47.

4. Yiannakopoulou E., Papadopulos J.S., Cokkinos D.V., Mountokalakis T.D. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005;12(3):243-9.

5. Menard J., Chatellier G. Limiting factors in the control of BP: why is there a gap between theory and practice? J Hum Hypertens 1995;9 Suppl 2:S19-23.

6. Andrade J.P., Vilas-Boas F., Chagas H., Andrade M. Epidemiological aspects of adherence to the treatment of hypertension. Arq Bras Cardiol 2002;79(4):375-84.

7. Sokol M.C., McGuigan K.A., Verbrugge R.R., Epstein R.S. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43(6):521-30.

8. Simpson S.H., Eurich D.T., Majumdar S.R. et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006;333(7557):15.

9. Rizzo J.A.,Abbott T.A. 3rd, Pashko S. Labour productivity effects of prescribed medicines for chronically ill workers. Health Econ 1996;5(3):249-65.

10. Van Wijk B.L., Klungel O.H., Heerdink E.R., de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005;23(11):2101-7.

11. Моисеев С.В., Фомин В.В. Блокаторы рецепторов ангиотензина II и сексуальная функция у мужчин и женщин. Клиническая фармакология и терапия 2006;15:1-4.

12. Rosen R.C. Sexual dysfunction as an obstacle to compliance with antihypertensive therapy. Blood Press Suppl 1997;1:47-51.

13. Ferrario C.M., Levy P. Sexual dysfunction in patients with hypertension: implications for therapy. J Clin Hypertens (Greenwich) 2002;4(6):424-32.

14. Верткин А.Л., Лоран О.Б., Тополянский А.В. и др. Клиническая эффективность и влияние b-адреноблокаторов на копулятивную функцию у больных с артериальной гипертензией. Кардиология 2002;42(9):39-42.

15. Подзолков В.И., Булатов В.А., Вигдорчик А.В. Антигипертензивная эффективность валсартана у курящих в сравнении с некурящими пациентами с артериальной гипертензией: первые результаты российского многоцентрового открытого исследования. Рациональная Фармакотерапия в Кардиологии 2010;6(1):29-36.

16. Rosen R.C., Riley A., Wagner G. et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49(6):822-30.

17. Пушкарь Д.Ю. Эректильная дисфункция – современные методы диагностики и лечения. Справочник поликлинического врача 2004;4(2):55-7.

18. Rosen R., Brown C., Heiman J. et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26(2):191-208.

19. Hermida R.C., Calvo C., Ayala D.E. et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 2003;42(3):283-90.

20. Hermida R.C., Calvo C., Ayala D.E. et al. Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens 2005;23(10):1913-22.

21. Calvo C., Hermida R.C., Ayala D.E., Ruilope L.M. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004;22(4):837-846.

22. Fogari R., Mugellini A., Zoppi A. et al. Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: A double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring. Curr Ther Res 2002;63:1-14.

23. Kyvelou S.M., Vyssoulis G.P., Karpanou E.A. et al. Beneficial effects of angiotensin II type 1 receptor blocker antihypertensive treatment on inflammation indices: the effect of smoking.J Clin Hypertens (Greenwich) 2007;9(1):21-7.

24. ReimsH.M.,Oparil S.,Kjeldsen S.E. et al. Losartanbenefits over atenolol in non-smokinghypertensive patients with left ventricular hypertrophy: the LIFE study. Blood Press 2004;13(6):376-84.

25. Zanchetti A., Julius S., Kjeldsen S. et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. J Hypertens 2006;24(11):2163-8.

26. Grimm R.H. Jr., Grandits G.A., Prineas R.J. et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997;29(1 Pt 1):8-14.

27. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed) 1985;291(6488):97-104.

28. Bohm M., Baumhakel M., Probstfield al. Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy ofthe ONgoing TelmisartanAlone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). Am Heart J 2007;154(1):94-101.

29. Fogelman J. Verapamil caused depression, confusion, and impotence [Letter]. Am J Psychiatry 1988;145(3):380.

30. Barksdale J.D., Gardner S.F: The impact offirst-line antihypertensive drugs on erectile dysfunction. Pharmacotherapy 1999;19(5):573-81.

31. Fogari R., Zoppi A., Corradi L. et al. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens 1998;11(10):1244-7.

32. LlisterriJ.L., Lozano VidalJ.V. et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001;321(5):336-41.

33. Della Chiesa A., Pfiffner D., Meier B., Hess O.M. Sexual activity in hypertensive men. J Hum Hypertens 2003;17(8):515-21.

34. Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003;2:29-34.

35. Fogari R., Preti P., Derosa G. et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002;58(3):177-80.

36. Fogari R., Zoppi A., Poletti L. et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001;14(1):27-31.

37. Fogari R., Preti P., Zoppi A. et al. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. Am J Hypertens 2004;17(1):77-81.

For citation:


Views: 575

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)